Prostate cancer screening

摘要

We took great interest in reading the review based on two randomized controlled trials on screening for prostate cancer. One of these is the "Norrkoping Study" conducted by our group. Unfortunately, the name of the journal had been omitted (Eur Urol) in the reference list.As noted by the authors, the impact on the quality of life, associated harms or cost was not mentioned in the article. These issues, however, have been addressed in previous reports. Our screening trial was primarily designed to study the acceptability, costs, psychosocial consequences, and organisation. Recently, we published a separate paper on costs and effects of prostate cancer screening in Sweden with 15 years follow-up including a decision model to calculate the total costs of the programme. Introducing our screening programme in Sweden would incur 244 million SEK (265 millionEuro) annually as additional costs for screening and treatment compared to a non-screening strategy.